Competitor Analysis: RORgamma Antagonists and Agonists
Competitor Analysis: RORgamma Antagonists and Agonists
This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (ROR?) for treatment of inflammatory diseases and cancer as of September 2019.
The transcription factor ROR? plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is therefore an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has been heightened by the advancement of orally and topically administered ROR? modulators into clinical trials.
Some studies found ROR? to be upregulated in cancer tissues compared with normal tissues. Furthermore, synthetic ROR? agonists modulate immune cell gene expression to increase effector T-cell activity and decrease immune suppression.
The report includes a compilation of currently active projects in research and development of RORgamma antagonists and agonists for treatment of inflammatory diseases and cancer, respectively. In addition, the report lists company-specific R&D pipelines of antagonists and agonists of RORgamma. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (ROR?) for treatment of inflammatory diseases and cancer as of September 2019.
The transcription factor ROR? plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is therefore an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has been heightened by the advancement of orally and topically administered ROR? modulators into clinical trials.
Some studies found ROR? to be upregulated in cancer tissues compared with normal tissues. Furthermore, synthetic ROR? agonists modulate immune cell gene expression to increase effector T-cell activity and decrease immune suppression.
The report includes a compilation of currently active projects in research and development of RORgamma antagonists and agonists for treatment of inflammatory diseases and cancer, respectively. In addition, the report lists company-specific R&D pipelines of antagonists and agonists of RORgamma. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.
1) RORGAMMA ANTAGONISTS/INVERSE AGONISTS FOR INFLAMMATORY DISEASES
2) RORGAMMA AGONISTS FOR CANCER
3) CORPORATE RORGAMMA ANTAGONIST & AGONIST R&D PIPELINES
2) RORGAMMA AGONISTS FOR CANCER
3) CORPORATE RORGAMMA ANTAGONIST & AGONIST R&D PIPELINES
